Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia

Abstract

The invention provides application of an alpha-L-fucosidase inhibitor deoxyfuconojirimycin or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating infantile viral pneumonia. The deoxyfuconojirimycin or the pharmaceutically acceptable salt thereof can inhibit virus activity, reduce lung index of a subject, reduce death rate, prolong survival time, inhibit inflammatory factor generation and reduce IFN-gamma, TNF-alpha and IL-6 levels.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of Deoxyfuconojirimycin or a pharmaceutically acceptable salt thereof in the preparation of medicines for preventing and / or treating infantile pneumonia in subjects. Background technique [0002] Pneumonia in children is a common disease in infancy and a common cause of death in infants and young children. Pneumonia is lung inflammation caused by pathogen infection or inhalation of amniotic fluid and oil, and allergic reactions. The main clinical manifestations are fever, cough, shortness of breath, dyspnea, and pulmonary rales. The early body temperature is 38-39°C. It can also be as high as 40°C. In addition to respiratory symptoms, children may have systemic symptoms such as listlessness, irritability, loss of appetite, and diarrhea. Infants often refuse to eat, choke on milk, vomit and have difficulty breathing. Pathogens that cause pneumonia in children i...

AI Technical Summary

Problems solved by technology

However, there is a lack of reports on the antiviral activity of α-L-fucosidase inhibitors structurally similar to α-D-glucosidase inhibitors in the prior art

Images